SITC 2016 Annual Meeting & Associated Programs
SITC 2016 Annual Meeting & Associated Programs

Society for Immunotherapy of Cancer (SITC)

2016 Annual Meeting & Associated Programs

Enduring Materials

Access slide decks and video via the links in the schedule below.

PDF = Click on presentation title to view .pdf version of slides

VIDEO = Presentation video is available; click on the icon to view 

Program Schedule
 

Wednesday, November 9, 2016
 

11:00 a.m. – 11:10 a.m. Welcome and Introductions
Daniel Chen, MD, PhD – Genentech 

Session I: New Agents in Development

Moderator: Adrian Bot, MD, PhD – Kite Pharma, Inc.  

11:10 a.m. – 11:15 a.m. Anti-Semaphorin4D VX15/2503 in Combination with Ipilimumab or Antibody to PD-1 or PD-L1  PDF  VIDEO
Elizabeth Evans, PhD - Vaccinex, Inc
11:15 a.m. – 11:20 a.m. IMO-2125, An Investigational Intratumoral Toll-Like Receptor 9 Agonist, Modulates the Tumor Microenvironment to Enhance Anti-Tumor Immunity  PDF  VIDEO
Mark Cornfeld, MD, MPH – Idera Pharmaceuticals
11:20 a.m. – 11:25 a.m. Cobimetinib in Combination with Atezolizumab  PDF  VIDEO
Edward Cha – Genentech
11:25 a.m. - 11:30 a.m. Combination Strategy for Varlilumab, An Agonist Anti-CD27 Monoclonal Antibody
Thomas Davis, MD – Celldex Therapeutics, Inc.
11:30 a.m.- 11:35 a.m. Safety of the Natural Killer (NK) Cell-Targeted Anti-KIR Antibody, lirilumab (liri), in Combination with Nivolumab (nivo) or Ipilimumab (ipi) in Two Phase 1 Studies in Advanced Refractory Solid Tumors  PDF  VIDEO
F. Stephen Hodi, MD – Dana-Farber Cancer Institute
11:35 a.m. - 11:40 a.m. A CD122-Biased Agonist Increases CD8+T Cells and Natural Killer Cells in the Tumor Microenvironment; Making Cold Tumors Hot with NKTR-214  PDF  VIDEO
Adi Diab, MD – MD Anderson Cancer Center
11:40 a.m. – 11:45 a.m.   Activated Natural Killer (aNK) Cell Therapy
Patrick Soon-Shiong, MD, FRCS, FACS – NantKwest

Session II: Pre-Clinical New Agents in Development
 

11:45 a.m. – 11:50 a.m.   CD3-EGFR Probody™ T Cell-Engaging Bispecific Induces Tumor Regressions and Substantially Increases Safety Window in Preclinical Studies  VIDEO
Bryan A. Irving, PhD – Cytomx Therapeutics, Inc.
11:50 a.m. – 11:55 a.m.  PRS-343, a CD137 (4-1BB)/HER2 Bispecific  PDF
Shane A. Olwill, PhD – Pieris Pharmaceuticals, Inc.
11:55 a.m. – 12:00 p.m. pLADD: Personalized, Live, Attenuated Double-Deleted Listeria Monocytogenes
Thomas W. Dubensky Jr., PhD – Aduro Biotech
12:00 p.m. – 12:05 p.m. CA170: A Small Molecule Orally Available Checkpoint Inhibitor  PDF  VIDEO
David Tuck, MD – Curis
12:05 p.m. – 12:10 p.m. LAG-3Ig (IMP321) in Combination with Anti-PD-1 Therapy  PDF  VIDEO
Frederic Triebel, MD, PhD – Prima Biomed Ltd
12:10 p.m. – 12:15 p.m. Agent A - PD-1 DNR-41BB: Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation
Prasad S. Adusumilli, MD, FACP, FCCP – Memorial Sloan Kettering Cancer Center
12:15 p.m. – 12:20 p.m. The Immunoreceptor TIGIT Regulates Anti-Tumor Immunity
Jane Grogan, PhD – Genentech
12:20 p.m. – 12:45 p.m. Audience Question & Answer
Adrian Bot, MD, PhD – Kite Pharma, Inc.

Session III: Strategic Considerations of Combinations and Biomarkers in New Agent Development 
 

1:30 p.m. – 2:00 p.m. Combinations & Biomarkers  PDF  VIDEO
Charles G. Drake, MD, PhD – Columbia University Herbert Irving Comprehensive Cancer Center
2:00 p.m. – 3:25 p.m. Extended Panel Discussion
Co-Chairs: 
Andrian Bot, MD, PhD – Kite Pharma, Inc.
Daniel Chen, MD, PhD – Genentech
Roger Dansey, MD – Merck & Co., Inc.
Ramy Ibrahim, MD – Parker Institute for Cancer Immunotherapy (formerly at AstraZeneca)
Salil Patel – Bristol-Myers Squibb
Faculty: 
Raj K. Puri, MD, PhD – U.S. Food & Drug Administration
Marc Theoret, MD – U.S. Food & Drug Administration
Charles G. Drake, MD, PhD – Columbia University Herbert Irving Comprehensive Cancer Center
Gordon J. Freeman, PhD – Dana-Farber Cancer Institute
3:25 p.m. – 3:30 p.m. Closing Remarks
Roger Dansey, MD – Merck & Co., Inc.
2016 Annual Meeting
2016 Annual Meeting
2016 Annual Meeting
2016 Annual Meeting
2016 Annual Meeting

Important Dates

Thank You, Supporters!

Thank you, SITC 2016 supporters. Because of your generosity, SITC 2016 was a great success!

Interested in supporting other SITC programs? Confirm your support today!

Connect with SITC!

SITC: Join Today

SITC: TWITTERSITC: LINKEDINSITC: YOUTUBESITC: ONCOLOGY TUBE